Payment overview · 2025
General Payments
$80,074.55
217 reported records · 29 companies
Healthcare provider profile · identity verified
Barry Dean Bertolet, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · TUPELO, MS · NPI 1295845444
Verified facts
What the public records show
CMS Open Payments records show Barry Dean Bertolet, MD received $80,074.55 in general payments during 2025 across 217 reported records.
Medtronic, Inc. accounted for 83.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 47 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Camzyos, Eliquis, Jardiance.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 180 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAMZYOS as an associated drug or biological on 41009 records involving 16400 distinct recipient NPIs. Public Medicare Part D data also shows 146 claims for Camzyos by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 482 claims for Eliquis by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 482 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$66,723.68 | 83.3% | 125 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $4,377.53 | 5.5% | 5 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $3,076.30 | 3.8% | 11 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $1,500.00 | 1.9% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $1,421.62 | 1.8% | 3 | 2025 |
| Thrombolex, Inc. | Unresolved — no canonical attribution shown | $426.53 | 0.5% | 3 | 2025 |
| W. L. Gore & Associates, Inc. | Unresolved — no canonical attribution shown | $356.42 | 0.5% | 7 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $293.58 | 0.4% | 7 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $245.94 | 0.3% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $231.69 | 0.3% | 5 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $191.50 | 0.2% | 10 | 2025 |
| Endologix LLC | Unresolved — no canonical attribution shown | $169.26 | 0.2% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $139.16 | 0.2% | 1 | 2025 |
| Bard Peripheral Vascular, Inc. | Unresolved — no canonical attribution shown | $133.57 | 0.2% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $116.52 | 0.1% | 3 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $100.86 | 0.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $94.72 | 0.1% | 5 | 2025 |
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $87.56 | 0.1% | 4 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $74.12 | 0.1% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $60.46 | 0.1% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $53.89 | 0.1% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $45.27 | 0.1% | 2 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $44.03 | 0.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $27.32 | 0.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.18 | 0.0% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $16.46 | 0.0% | 1 | 2025 |
| BIOTRONIK INC. | Unresolved — no canonical attribution shown | $16.36 | 0.0% | 1 | 2025 |
| Chiesi USA, Inc. | Unresolved — no canonical attribution shown | $15.78 | 0.0% | 1 | 2025 |
| Cook Medical LLC | Unresolved — no canonical attribution shown | $15.24 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $44,800.00 | 11 |
| Consulting Fee | $20,397.50 | 9 |
| Travel and Lodging | $8,558.20 | 52 |
| Food and Beverage | $5,846.06 | 142 |
| Education | $472.79 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $62,493.61 | 88 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $4,317.50 | 2 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $1,500.00 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $1,421.62 | 3 | 2025 |
Source payment records
|
|||||
| RESOLUTE ONYX Normalized: resolute onyx |
Device | Medtronic, Inc. | $472.79 | 3 | 2025 |
Source payment records
|
|||||
| Bashir Endovascular Catheter Normalized: bashir endovascular catheter |
Device | Thrombolex, Inc. | $426.53 | 3 | 2025 |
Source payment records
|
|||||
| GORE CARDIOFORM Septal Occluder Normalized: gore cardioform septal occluder |
Device | W. L. Gore & Associates, Inc. | $248.04 | 5 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $191.50 | 10 | 2025 |
Source payment records
|
|||||
| Ambulatory Monitoring & Diagnostics Undivided Normalized: ambulatory monitoring diagnostics undivided |
Device | Philips North America LLC | $179.55 | 4 | 2025 |
Source payment records
|
|||||
| ENDOCROSS Device Normalized: endocross device |
Device | Endologix LLC | $169.26 | 1 | 2025 |
Source payment records
|
|||||
| Torus Stent Graft System Normalized: torus stent graft system |
Device | Endologix LLC | $169.26 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $165.60 | 8 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $139.16 | 1 | 2025 |
Source payment records
|
|||||
| General - Vascular Intervention Normalized: general vascular intervention |
Device | Boston Scientific Corporation | $135.77 | 1 | 2025 |
Source payment records
|
|||||
| RotarexS 6 F x 135 cm Normalized: rotarexs 6 f x 135 cm |
Device | Bard Peripheral Vascular, Inc. | $133.57 | 1 | 2025 |
Source payment records
|
|||||
| XACT Normalized: xact |
Device | Abbott Laboratories | $132.27 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $125.42 | 7 | 2025 |
Source payment records
|
|||||
| GORE CARDIOFORM ASD Occluder Normalized: gore cardioform asd occluder |
Device | W. L. Gore & Associates, Inc. | $108.38 | 2 | 2025 |
Source payment records
|
|||||
| FFRANGIO Normalized: ffrangio |
Device | Medtronic, Inc. | $106.50 | 3 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $100.86 | 1 | 2025 |
Source payment records
|
|||||
| NAVITOR Normalized: navitor |
Device | Abbott Laboratories | $100.28 | 1 | 2025 |
Source payment records
|
|||||
| Coronary Other Normalized: coronary other |
Device | Philips North America LLC | $92.61 | 2 | 2025 |
Source payment records
|
|||||
| Indigo System Normalized: indigo system |
Device | Penumbra, Inc. | $87.56 | 4 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $74.12 | 4 | 2025 |
Source payment records
|
|||||
| OptiCross 6 Normalized: opticross 6 |
Device | Boston Scientific Corporation | $69.33 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $60.03 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $57.52 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $53.89 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $45.27 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $45.27 | 2 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $44.03 | 1 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $30.38 | 2 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $30.08 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $29.35 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $27.32 | 1 | 2025 |
Source payment records
|
|||||
| Ranger Normalized: ranger |
Device | Boston Scientific Corporation | $26.59 | 3 | 2025 |
Source payment records
|
|||||
| MCOT Normalized: mcot |
Device | Philips North America LLC | $21.42 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.18 | 1 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $16.46 | 1 | 2025 |
Source payment records
|
|||||
| Orsiro Mission Normalized: orsiro mission |
Device | BIOTRONIK INC. | $16.36 | 1 | 2025 |
Source payment records
|
|||||
| CLEVIPREX Normalized: cleviprex |
Drug | Chiesi USA, Inc. | $15.78 | 1 | 2025 |
Source payment records
|
|||||
| KENGREAL Normalized: kengreal |
Drug | Chiesi USA, Inc. | $15.78 | 1 | 2025 |
Source payment records
|
|||||
| ZILVER PTX Normalized: zilver ptx |
Device | Cook Medical LLC | $15.24 | 1 | 2025 |
Source payment records
|
|||||
| ESPRIT Normalized: esprit |
Device | Abbott Laboratories | $13.39 | 1 | 2025 |
Source payment records
|
|||||
| AZURE XT DR MRI SURESCAN Normalized: azure xt dr mri surescan |
Device | Medtronic, Inc. | $9.33 | 1 | 2025 |
Source payment records
|
|||||
| MYCARELINK Normalized: mycarelink |
Device | Medtronic, Inc. | $7.20 | 1 | 2025 |
Source payment records
|
|||||
| ONYX FRONTIER Normalized: onyx frontier |
Device | Medtronic, Inc. | $4.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CAMZYOS camzyos |
2025 | Camzyos | 2024 | 146 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 482 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 96 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
62 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
180 | 43 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
96 | 22 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | CAMZYOS open payments reported associated product |
CMS Open Payments — General Payments 41009 supporting records · 16400 recipient NPIs · example record 1184377697 |
Camzyos · 2024 Exact normalized brand match · 1 Part D row |
146 | 19 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
482 | 99 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
95 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
482 | 99 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1232 | 389 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1026 | 343 |
| Ezetimibe | Ezetimibe | 874 | 263 |
| Metoprolol Succinate | Metoprolol Succinate | 874 | 270 |
| Clopidogrel | Clopidogrel Bisulfate | 739 | 218 |
| Carvedilol | Carvedilol | 727 | 231 |
| Losartan Potassium | Losartan Potassium | 676 | 206 |
| Amlodipine Besylate | Amlodipine Besylate | 561 | 184 |
| Eliquis | Apixaban | 482 | 99 |
| Spironolactone | Spironolactone | 445 | 137 |
| Propafenone Hcl | Propafenone Hcl | 397 | 112 |
| Hydrochlorothiazide | Hydrochlorothiazide | 388 | 128 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 362 | 112 |
| Lisinopril | Lisinopril | 322 | 109 |
| Amiodarone Hcl | Amiodarone Hcl | 243 | 71 |
| Repatha Sureclick | Evolocumab | 227 | 46 |
| Furosemide | Furosemide | 204 | 95 |
| Farxiga | Dapagliflozin Propanediol | 180 | 43 |
| Pantoprazole Sodium | Pantoprazole Sodium | 176 | 52 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 173 | 54 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 163 | 58 |
| Ranolazine Er | Ranolazine | 159 | 36 |
| Xarelto | Rivaroxaban | 158 | 26 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 149 | 48 |
| Camzyos | Mavacamten | 146 | 19 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 140 | 44 |
| Potassium Chloride | Potassium Chloride | 134 | 48 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 133 | 46 |
| Metoprolol Tartrate | Metoprolol Tartrate | 131 | 53 |
| Doxazosin Mesylate | Doxazosin Mesylate | 125 | 42 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 117 | 35 |
| Nebivolol Hcl | Nebivolol Hcl | 107 | 41 |
| Pravastatin Sodium | Pravastatin Sodium | 103 | 35 |
| Torsemide | Torsemide | 98 | 41 |
| Jardiance | Empagliflozin | 96 | 22 |
| Entresto | Sacubitril/Valsartan | 95 | 19 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 94 | 40 |
| Fenofibrate | Fenofibrate | 84 | 31 |
| Flecainide Acetate | Flecainide Acetate | 81 | 19 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 81 | 30 |
| Praluent Pen | Alirocumab | 80 | 16 |
| Warfarin Sodium | Warfarin Sodium | 78 | 23 |
| Simvastatin | Simvastatin | 75 | 28 |
| Valsartan | Valsartan | 75 | 27 |
| Prasugrel Hcl | Prasugrel Hcl | 69 | 16 |
| Sotalol | Sotalol Hcl | 68 | 20 |
| Levothyroxine Sodium | Levothyroxine Sodium | 67 | 21 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 66 | 20 |
| Brilinta | Ticagrelor | 62 | 15 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 60 | 18 |
| Digoxin | Digoxin | 52 | 18 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 45 | 14 |
| Nitroglycerin | Nitroglycerin | 45 | 35 |
| Irbesartan | Irbesartan | 43 | 12 |
| Midodrine Hcl | Midodrine Hcl | 42 | suppressed |
| Omeprazole | Omeprazole | 42 | 14 |
| Cilostazol | Cilostazol | 41 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 41 | 13 |
| Atenolol | Atenolol | 39 | 14 |
| Propranolol Hcl | Propranolol Hcl | 35 | 13 |
| Diltiazem 24hr Er | Diltiazem Hcl | 34 | 13 |
| Ramipril | Ramipril | 34 | 12 |
| Benazepril Hcl | Benazepril Hcl | 32 | 12 |
| Chlorthalidone | Chlorthalidone | 30 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 30 | suppressed |
| Vascepa | Icosapent Ethyl | 27 | suppressed |
| Clonidine | Clonidine | 26 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 26 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 25 | suppressed |
| Cartia Xt | Diltiazem Hcl | 22 | 12 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 21 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 20 | suppressed |
| Telmisartan | Telmisartan | 19 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 15 | suppressed |
| Prednisone | Prednisone | 14 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 12 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 11 | suppressed |
| Famotidine | Famotidine | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $80,074.55 · 217 records | Medtronic, Inc. | AREXVY, AZURE XT DR MRI SURESCAN, Ambulatory Monitoring & Diagnostics Undivided, Bashir Endovascular Catheter, CAMZYOS, CAPVAXIVE, CLEVIPREX, Coronary Other, ELIQUIS, ENDOCROSS Device, ESPRIT, FFRANGIO, FUROSCIX, GORE CARDIOFORM ASD Occluder, GORE CARDIOFORM Septal Occluder, General - Vascular Intervention, INJECTAFER, INSPIRE, Indigo System, JARDIANCE, KENGREAL, Kerendia, LEQVIO, LOKELMA, MCOT, MYCARELINK, NAVITOR, NEXLETOL, NURTEC ODT, ONPATTRO, ONYX FRONTIER, OptiCross 6, Orsiro Mission, Ozempic, REPATHA, RESOLUTE ONYX, Ranger, RotarexS 6 F x 135 cm, SHINGRIX, SYMPLICITY G3, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, Torus Stent Graft System, VERQUVO, WAINUA, Wegovy, XACT, ZILVER PTX | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Camzyos play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error